Chonnam Med J.
2003 Mar;39(1):1-6.
Immunotherapy using Dendritic Cells against Acute Myelogenous Leukemia
- Affiliations
-
- 1Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. hjoonk@ chonnam.ac.kr
- 2Department of Pathology, Chonnam National University Medical School, Gwangju, Korea.
- 3Genome Research Center for Hematopoietic Diseases, Chonnam National University Hospital, Gwangju, Korea.
- 4Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.
Abstract
- Dendritic cells (DC) are the most potent antigen presenting cells (APC) for initiating cellular immune responses through the stimulation of naive T cells. DC have now moved to the main stage of active cancer immunotherapy. Leukemic cells evade host immune surveillance by lacking expression of co-stimulatory molecules or adhesion molecules. Thus, it may be possible to treat patients with leukemia by manipulation of the immune system using APC with increased potency, such as DC. This mini-review will focus mainly on immunological approaches using monocyte-derived DC with leukemic antigens and leukemic cell-derived DC to the therapy of acute myelogenous leukemia.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Effectiveness of IL-12 Administration and Fusion on Tumor Antigen Sensitization Methods for Dendritic Cells Derived from Patients with Myelogenous Leukemia
- Clinical Experience of Leukemia with Extradural Chloroma during Treatment of Lower Back Pain
- In vitro Culture of Dendritic Cells and Activation of Peripheral Blood Mononuclear Cells in Patients with Chronic Myelogenous Leukemia
- Sweet's Syndrome with Myelodysplastic Syndrome Progressing to Acute Myelogenous Leukemia
- Multiple Granulocytic Sarcomas in a Patient with Longstanding Complete Remission of Acute Myelogenous Leukemia
